(Q53898460)

22 May 2018

title

Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. (English)

1 reference

22 May 2018

1

P Ljungman

1 reference

22 May 2018

P Reusser

2

1 reference

22 May 2018

R de la Camara

3

1 reference

22 May 2018

H Einsele

4

1 reference

22 May 2018

D Engelhard

5

1 reference

22 May 2018

P Ribaud

6

1 reference

22 May 2018

K Ward

7

1 reference

22 May 2018

European Group for Blood and Marrow Transplantation

8

1 reference

22 May 2018

language of work or name

English

0 references

publication date

1 June 2004

1 reference

22 May 2018

Bone Marrow Transplantation

published in

1 reference

22 May 2018

volume

33

1 reference

22 May 2018

issue

11

1 reference

22 May 2018

page(s)

1075-1081

1 reference

22 May 2018

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704505

exact match

0 references

cites work

Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

Evaluation of the Murex CMV DNA Hybrid Capture assay (version 2.0) for early diagnosis of cytomegalovirus infection in recipients of an allogeneic stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

A real-time TaqMan PCR for routine quantitation of cytomegalovirus DNA in crude leukocyte lysates from stem cell transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

Definitions of cytomegalovirus infection and disease in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

Cytomegalovirus (CMV)-Specific Intravenous Immunoglobulin for the Prevention of Primary CMV Infection and Disease after Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

Viral dynamics during active cytomegalovirus infection and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

CMV retinitis after allogeneic bone marrow transplantation: a report of five cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

Treatment of Interstitial Pneumonitis Due to Cytomegalovirus with Ganciclovir and Intravenous Immune Globulin: Experience of European Bone Marrow Transplant Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

CMV pneumonia in allogeneic BMT recipients undergoing early treatment or pre-emptive ganciclovir therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

7 January 2021

Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

7 January 2021

Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

7 January 2021

A three-center European external quality control study of PCR for detection of cytomegalovirus DNA in blood

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

7 January 2021

Quantitation of cytomegalovirus: methodologic aspects and clinical applications.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

7 January 2021

Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

7 January 2021

Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

7 January 2021

Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

7 January 2021

Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

7 January 2021

Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

7 January 2021

Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

7 January 2021

No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

7 January 2021

Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

7 January 2021

Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

7 January 2021

A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

7 January 2021

Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

7 January 2021

Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT). Infecti

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

7 January 2021

Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704505

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704505

1 reference

22 May 2018

1 reference

22 May 2018